All In Biotech

Drug Trial Radar · NCT04920786

Sequential Dose-escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of TB006 in Healthy Subjects

A Phase 1 Double-blind, Randomized, Single Dose, Sequential Dose-escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of TB006 in Healthy Subjects

Last checked: Nov 19, 2026Latest source record: Dec 9, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

48

Actual

Start

Jun 1, 2021

Primary completion

May 3, 2022

Study completion May 3, 2022

Sponsor

Lead sponsor
TrueBinding, Inc.Industry
Sponsor type
Industry
First posted
Jun 10, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a single dose, dose-escalation study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of TB006, a monoclonal antibody that will be studied as a disease modifying treatment for Alzheimer's disease.

Conditions

  • Alzheimer Disease

Interventions

  • TB006Drug

    TB006

  • Sterile saline (Placebo)Other

    Sterile saline

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of subjects and rate of treatment-emergent adverse events, graded by CTCAE Version 5.0, by dose group and all active treatment vs. placeboTime frame: Day1-Day 75
  2. To determine the single-dose PK profile of TB006 in healthy adult subjectsTime frame: Through day 75
  3. To determine the MTD of single doses of TB006 in healthy adult subjectsTime frame: Through day 75

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Collaborative Neuroscience Research, LLC (CNS)

    Long Beach, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.